Equillium, Inc. (EQ)Healthcare | Biotechnology | La Jolla, United States | NasdaqCM
1.30 USD
-0.02
(-1.515%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:30 a.m. EDT
The investment case for Equillium is currently defined by a stark disconnect between optimistic analyst targets and deteriorating operational reality. While analysts project a mean price of $8.56, the company is burning cash aggressively with negative free cash flow and a trailing EPS of -$0.14. The balance sheet, though currently bolstered by significant cash reserves, cannot indefinitely fund operations without a successful commercialization of its lead asset, EQ504. The market appears to be pricing in a failure of Phase 1 success, as noted in recent commentary. From a technical standpoint, the stock is trading well below its 50-day and 200-day moving averages, confirming a downtrend. The options market reinforces this bearish sentiment, with heavy put buying at strikes far above the current price, signaling a fear of a deep correction. Without evidence of sustained revenue growth or a turnaround in profitability, the business faces the classic risks of a biotech firm: high burn rate and execution risk. The short-term outlook remains weak due to these technical and fundamental headwinds, while the long-term potential is capped by the lack of proven product-market fit and the severe financial drag. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.141745 |
| AutoETS | 0.141752 |
| MSTL | 0.150723 |
| AutoTheta | 0.184278 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 4.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.037 |
| Excess Kurtosis | 0.19 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.043 |
| Market Cap | 82,430,504 |
| Forward P/E | -5.48 |
| Beta | 1.92 |
| Website | https://www.equilliumbio.com |
As of Oct. 10, 2026, 4:30 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest is concentrated significantly deeper in-the-money at the $5.00 strike compared to the $2.50 strike, suggesting a fear of a substantial drop below current levels. Conversely, call open interest is entirely out-of-the-money, indicating no speculative bets on immediate rallies. Implied volatility for puts is markedly elevated relative to calls, reflecting heightened anxiety about potential losses.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.056910515 |
| Address1 | 2,223 Avenida De La Playa |
| Address2 | Suite 105 |
| All Time High | 27.05 |
| All Time Low | 0.27 |
| Ask | 1.38 |
| Ask Size | 9 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 520,470 |
| Average Daily Volume3 Month | 545,443 |
| Average Volume | 545,443 |
| Average Volume10Days | 520,470 |
| Beta | 1.918 |
| Bid | 1.39 |
| Bid Size | 1 |
| Book Value | 0.883 |
| City | La Jolla |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.3 |
| Current Ratio | 23.396 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.38 |
| Day Low | 1.3 |
| Debt To Equity | 1.043 |
| Display Name | Equillium |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -19,200,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.346 |
| Enterprise Value | 25,850,506 |
| Eps Current Year | -0.20571 |
| Eps Forward | -0.23714 |
| Eps Trailing Twelve Months | -0.14 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.9854 |
| Fifty Day Average Change | -0.6854 |
| Fifty Day Average Change Percent | -0.34522012 |
| Fifty Two Week Change Percent | 5.6910515 |
| Fifty Two Week High | 3.54 |
| Fifty Two Week High Change | -2.24 |
| Fifty Two Week High Change Percent | -0.6327684 |
| Fifty Two Week Low | 0.76 |
| Fifty Two Week Low Change | 0.53999996 |
| Fifty Two Week Low Change Percent | 0.7105263 |
| Fifty Two Week Range | 0.76 - 3.54 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,539,351,000,000 |
| Float Shares | 36,965,010 |
| Forward Eps | -0.23714 |
| Forward P E | -5.4819937 |
| Free Cashflow | -14,297,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Fullday Change | -0.004999995 |
| Fullday Change Percent | -0.3787875 |
| Fullday Price | 1.3 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15999 |
| Held Percent Institutions | 0.65756 |
| Implied Shares Outstanding | 63,408,082 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. |
| Long Name | Equillium, Inc. |
| Market | us_market |
| Market Cap | 82,430,504 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_575585027 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -18,009,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 110,964,143 |
| Number Of Analyst Opinions | 9 |
| Open | 1.32 |
| Operating Cashflow | -19,972,000 |
| Operating Margins | 0.0 |
| Phone | 858 240 1200 |
| Previous Close | 1.32 |
| Price Eps Current Year | -6.3195763 |
| Price Hint | 4 |
| Price To Book | 1.4722536 |
| Profit Margins | 0.0 |
| Quick Ratio | 23.069 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.11111 |
| Region | US |
| Regular Market Change | -0.0200001 |
| Regular Market Change Percent | -1.515159 |
| Regular Market Day High | 1.38 |
| Regular Market Day Low | 1.3 |
| Regular Market Day Range | 1.3 - 1.38 |
| Regular Market Open | 1.32 |
| Regular Market Previous Close | 1.32 |
| Regular Market Price | 1.3 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 263,691 |
| Return On Assets | -0.3395 |
| Return On Equity | -0.58976 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 63,408,082 |
| Shares Percent Shares Out | 0.0874 |
| Shares Short | 5,541,054 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,369,936 |
| Short Name | Equillium, Inc. |
| Short Percent Of Float | 0.1013 |
| Short Ratio | 8.51 |
| Source Interval | 15 |
| State | CA |
| Symbol | EQ |
| Target High Price | 20.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 8.55556 |
| Target Median Price | 7.0 |
| Total Cash | 57,164,000 |
| Total Cash Per Share | 0.902 |
| Total Debt | 584,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.14 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.07905 |
| Two Hundred Day Average Change | -0.7790501 |
| Two Hundred Day Average Change Percent | -0.37471446 |
| Type Disp | Equity |
| Volume | 263,691 |
| Website | https://www.equilliumbio.com |
| Zip | 92,037 |